Skip to main content

Table 3 The effects of low vs high dose regimen of sildenafil on exercise capacity and echocardiographic variables

From: Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study

  Sildenafil
Low dose effect (Baseline – 3 months) High-dose effect (3 months – 6 months) Overall treatment effect
PVR, Wood units −0.56 (95% CI − 0.70 to − 0.42)** −0.09 (95% CI − 0.20 to 0.02) −0.65 (95% CI − 0.76 to − 0.53)**
RVOT acceleration time, ms 29 (95% CI 20 to 38)** 2 (95% CI −5 to 10) 31 (95% CI 23 to 40)**
TAPSE, cm 0.25 (95% CI 0.18 to 0.31)** 0.17 (95% CI 0.10 to 0.25)†† 0.42 (95% CI 0.32 to 0.52)**
RV basal diameter, cm −0.18 (95% CI − 0.26 to − 0.10)** −0.12 (95% CI − 0.21 to − 0.04)†† −0.30 (95% CI − 0.42 to − 0.18)**
Mitral e′, cm/s 0.8 (95% CI 0.5 to 1.0)** 0.2 (95% CI − 0.1 to 0.5) 1.0 (95% CI 0.6 to 1.3)**
Mitral E/e′ ratio −1.2 (95% CI − 2.0 to − 0.5)** −1.1 (95% CI − 1.8 to − 0.4)†† − 2.4 (95% CI − 3.3 to − 1.4)**
LV mass index, g/m2 −12 (95% CI − 21 to − 4)** −12 (95% CI − 20 to − 4)†† −24 (95% CI − 34 to − 14)**
  1. Е Early inflow velocity, e′ Annulus relaxation velocity, IVC inferior vena cava, LV left ventricular, OT outflow tract, PVR Pulmonary vascular resistance, RV Right ventricular; TAPSE Tricuspid annular plane systolic excursion
  2. *P < 0.05, **P < 0.01 vs baseline
  3. р < 0.05, and ††р < 0.01 vs 3 month exam